Liquidia (NASDAQ:LQDA) CAO Dana Boyle Sells 5,101 Shares
by Scott Moore · The Cerbat GemLiquidia Corporation (NASDAQ:LQDA – Get Free Report) CAO Dana Boyle sold 5,101 shares of the stock in a transaction on Monday, April 13th. The shares were sold at an average price of $38.37, for a total value of $195,725.37. Following the sale, the chief accounting officer directly owned 176,918 shares in the company, valued at approximately $6,788,343.66. The trade was a 2.80% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.
Dana Boyle also recently made the following trade(s):
- On Monday, January 26th, Dana Boyle sold 1,580 shares of Liquidia stock. The stock was sold at an average price of $41.65, for a total value of $65,807.00.
Liquidia Price Performance
LQDA stock traded down $0.14 during trading on Tuesday, hitting $38.71. The stock had a trading volume of 844,813 shares, compared to its average volume of 1,775,539. Liquidia Corporation has a 1-year low of $11.85 and a 1-year high of $46.67. The stock has a market cap of $3.41 billion, a price-to-earnings ratio of -46.64 and a beta of 0.45. The company’s 50 day moving average price is $36.87 and its two-hundred day moving average price is $32.92. The company has a debt-to-equity ratio of 2.97, a quick ratio of 1.84 and a current ratio of 2.01.
Liquidia (NASDAQ:LQDA – Get Free Report) last issued its quarterly earnings results on Thursday, March 5th. The company reported $0.15 EPS for the quarter, topping analysts’ consensus estimates of $0.08 by $0.07. The business had revenue of $92.02 million during the quarter, compared to the consensus estimate of $87.49 million. Liquidia had a negative net margin of 43.53% and a negative return on equity of 209.33%. The firm’s revenue for the quarter was up 3072.4% on a year-over-year basis. On average, sell-side analysts forecast that Liquidia Corporation will post -1.51 EPS for the current fiscal year.
Hedge Funds Weigh In On Liquidia
Hedge funds have recently made changes to their positions in the stock. Farallon Capital Management LLC grew its stake in shares of Liquidia by 102.1% during the 3rd quarter. Farallon Capital Management LLC now owns 8,565,638 shares of the company’s stock valued at $194,783,000 after buying an additional 4,326,876 shares during the period. TCG Crossover Management LLC purchased a new position in shares of Liquidia in the 3rd quarter worth $38,887,000. Caprock Group LLC purchased a new position in shares of Liquidia in the 3rd quarter worth $37,114,000. MPM Bioimpact LLC boosted its holdings in Liquidia by 600.4% in the fourth quarter. MPM Bioimpact LLC now owns 1,400,869 shares of the company’s stock valued at $48,316,000 after acquiring an additional 1,200,869 shares during the last quarter. Finally, Voloridge Investment Management LLC acquired a new position in Liquidia in the third quarter valued at $12,571,000. Institutional investors and hedge funds own 64.54% of the company’s stock.
Wall Street Analysts Forecast Growth
A number of brokerages have weighed in on LQDA. HC Wainwright increased their price target on Liquidia from $50.00 to $55.00 and gave the stock a “buy” rating in a research note on Friday, March 6th. BTIG Research lifted their price objective on Liquidia from $49.00 to $50.00 and gave the company a “buy” rating in a research report on Thursday, March 5th. Raymond James Financial reiterated a “strong-buy” rating on shares of Liquidia in a research note on Thursday, March 5th. Jefferies Financial Group raised their price target on Liquidia from $45.00 to $55.00 and gave the stock a “buy” rating in a research note on Tuesday, January 13th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Liquidia in a report on Thursday, January 22nd. Two research analysts have rated the stock with a Strong Buy rating, seven have assigned a Buy rating, one has assigned a Hold rating and two have given a Sell rating to the company’s stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $43.44.
Check Out Our Latest Analysis on Liquidia
Liquidia Company Profile
Liquidia Technologies, Inc is a clinical-stage biopharmaceutical company headquartered in Research Triangle Park, North Carolina. The company leverages its proprietary PRINT® (Particle Replication In Non-wetting Templates) platform to engineer precisely shaped and sized drug particles, with the goal of improving delivery, efficacy and safety profiles. By controlling particle characteristics at the nanoscale, Liquidia seeks to enhance respiratory and other therapies that depend on targeted delivery.
The company’s lead product candidate, LIQ861, is a dry powder formulation of treprostinil designed for inhalation in patients with pulmonary arterial hypertension (PAH).